study of interest: CAL101 for refractory indolent NHL/SLL

[Guest guest]

Efficacy and Safety Study of CAL-101 in Patients With [refractory] Indolent

B-Cell Non-Hodgkin Lymphoma

http://bit.ly/fIVVoy

refractory: (not responsive or inadequate response) both to rituximab AND to

alkylating-agent-containing chemotherapy. The primary objective will be to

assess the overall response rate.

Cannon Research Institute Recruiting

Nashville, Tennessee, United States, 37203

Contact: Ask SARAH 877-MY-1-SCRI (691-7274) asksarah@...

Principal Investigator: Ian Flinn, MD

Limited to:

â—¦Follicular lymphoma (FL)

â—¦Small lymphocytic lymphoma (SLL) with absolute lymphocyte count

â—¦Lymphoplasmacytoid lymphoma (LPL)

â—¦Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal)

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm